Global Innovation Forum 2022 Global Innovation Forum 2022

HUMAN BIONICS(Columbia)

We believe in a World without limitations

#Parkinson #andahumanbionics #parkinsondevice

Category:

Health Tech

Robotics

AR・VR・MR

Overview:
Human Bionics SAS has been developed an APP called ANDA connected to a pair of glasses that reproduce rhythms, sounds and orders specialized for Parkinson patients. These sounds can help them to unfreeze the gait that produces the Parkinson disease.

Advantages of our technology:
ANDA, it´s an app that arises after medical and scientific research in order to improve the quality of life of people with Parkinson's disease who have trouble walking. This technology is based on specialized rhythms and voices that are able to unlock the stiffness of the March by 30% or more than agreement to the training of the person. Also, this app helps the user to increase the production of dopamine and thus improve the stability and coordination of gait. In addition, you can keep track of the user's treatment in the measurement module and the statistics module, evaluating the evolution over time. By means of this device in its genre in the world that we designed, we have achieved that 120 people may have a tool at home which helps them have a more confident, natural and free gear. Currently, Anda works as a device in the shape of glasses, connected by Bluetooth to the app so that people regain confidence in your walk, reduce the incidence of falls and fractures and improve your quality of life.

Our aim for business:
[Target department / division/ companies]
We would like to meet with technology companies that makes medical developments and anothers that use internet of things. Marketing will be good, business development too.

[Principle Objective of exhibiting at GIF]
To find partners for technical tie-ups
To find joint venture partners
To find sales representatives
To find PoC partners
To find users

Recommended by

International Division, Osaka Chamber of
Commerce and Industry (OCCI)

TEL:+81-6-6944-6400

ページトップへ